Speaker: Dr. Oskar Hansson

Moderator: Dr. Carmela Tartaglia

Dr. Oskar Hansson gained his PhD in neurobiology in 2001 and his M.D. in 2005. He became senior consultant in neurology in 2012 at Skåne University Hospital, and full professor of neurology in 2017 at Lund University, Sweden. Dr. Oskar Hansson performs internationally recognized clinical and translational research focusing on the early phases of Alzheimer's and Parkinson’s diseases. His work on biomarkers has led to over 400 original peer-reviewed publications. He heads the prospective and longitudinal Swedish BioFINDER studies (www.biofinder.se), where the research team focuses on the development of optimized diagnostic algorithms for early diagnosis, and also studies the consequences of different brain pathologies on cognitive, neurologic and psychiatric symptoms in healthy individuals and patients with dementia and parkinsonian disorders. Recently, the BioFINDER team has shown that Tau PET imaging can with high accuracy distinguish Alzheimer’s from all other neurodegenerative diseases (JAMA, 2018), predict cognitive decline in cognitively normal individuals (Nature Medicine, 2022), and to detect different subtypes of Alzheimer’s (Nature Medicine 2021). He has also developed and validated blood-based biomarkers for early detection of Alzheimer’s disease (Nature Medicine, 2020; JAMA, 2020, Nature Aging 2021, Nature Medicine 2021, Nature Medicine 2022). He is the co-director of the strategic research area of neuroscience at Lund University, and responsible for research at the Memory Clinic at Skåne University Hospital.